HOLON, Israel, Jan. 14,
2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a
clinical-stage cancer immunotherapy company and leader in
predictive target discovery, today announced that its Phase 1
clinical trial evaluating COM701, a first-in-class therapeutic
antibody targeting PVRIG, will be featured in a trial-in-progress
poster at The ASCO-SITC Clinical Immuno-Oncology Symposium, taking
place February 28-March 2, 2019, in
San Francisco, CA.
The poster titled "A Phase 1 Study Evaluating COM701 in Patients
With Advanced Solid Tumors," will be presented by Drew W. Rasco, M.D, Associate Director of
Clinical Research at the South Texas Accelerated Research
Therapeutics (START), San Antonio,
TX and a Principal Investigator in the Phase 1 COM701
study.
The poster abstract is expected to be published on the
conference website on February 25, 2019, and will reflect
enrolment information as of the date of the abstract submission.
The poster presentation will take place on Thursday, February 28, 2019, and will include
updated enrolment information.
The poster will be available on Compugen's website at
www.cgen.com following the conference presentation.
About Compugen
Compugen is a clinical-stage, therapeutic discovery and
development company utilizing its broadly applicable predictive
discovery infrastructure to identify novel drug targets and develop
first-in-class therapeutics in the field of cancer immunotherapy.
The Company's therapeutic pipeline consists of immuno-oncology
programs against novel drug targets it has discovered, including T
cell immune checkpoints and myeloid target programs. Compugen's
business model is to selectively enter into collaborations for its
novel targets and related drug product candidates at various stages
of research and development. The Company is headquartered in
Israel with R&D facilities in
both Israel and South San Francisco, CA. Compugen's ordinary
shares are listed on Nasdaq and the Tel Aviv Stock Exchange under
the ticker symbol CGEN. For additional information, please visit
Compugen's corporate website at www.cgen.com.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
terminology such as "will," "may," "expects," "anticipates,"
"believes," "potential," "plan," "goal," "estimate," "likely,"
"should," "confident," and "intends," and describe opinions about
possible future events. These forward-looking statements involve
known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Among
these risks: Compugen's business model is substantially dependent
on entering into collaboration agreements with third parties and
Compugen may not be successful in generating adequate revenues or
commercializing aspects of its business model. Moreover, the
development and commercialization of therapeutic candidates involve
many inherent risks, including failure to progress to clinical
trials or, if they progress to or enter clinical trials, failure to
receive regulatory approval. These and other factors, including the
ability to finance the Company, are more fully discussed in the
"Risk Factors" section of Compugen's most recent Annual Report on
Form 20-F as filed with the Securities and Exchange Commission
(SEC) as well as other documents that may be subsequently filed by
Compugen from time to time with the SEC. In addition, any
forward-looking statements represent Compugen's views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Company contact:
Elana
Holzman
Director, Investor Relations and Corporate
Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972 (3) 765-8124
Investor Relations contact:
Burns McClellan,
Inc.
Jill Steier
Email: jsteier@burnsmc.com
Tel: 212-213-0006
View original
content:http://www.prnewswire.com/news-releases/compugens-phase-1-trial-of-com701-featured-as-a-trial-in-progress-at-the-asco-sitc-clinical-immuno-oncology-symposium-300777515.html
SOURCE Compugen Ltd.